Tolerance-efficacy outcome of one year of tacrine utilization in 100 Alzheimer's disease cases;BILAN TOLERANCE-EFFICACITE D'UN AN D'UTILISATION DE LA TACRINE DANS 100 CAS DE MALADIE D'ALZHEIMER

Therapie

Volumn 53, Issue 1, 1998, Pages 67-76

  Estadieu, M C ^a   Machou, C ^a   Berthezene P ^b   Pastor, M J ^c   Angelini, B ^a   Bohor, M ^a   Bongrand, M C ^a   Timon David, P ^a   Gastaut, J L ^c   Allain, H ^d   Michel, B F ^c  

^a HÔPITAL DE LA CONCEPTION   (France)

^b INSERM   (France)

^c Hopitaux Sud AP HM   (France)

^d Inst de Rech Contre le Cancer IRCC   (France)

Author keywords

Alzheimer'; Clinical efficacy; Safety; Tacrine (Cognex( )

Indexed keywords

TACRINE; ALANINE AMINOTRANSFERASE; NOOTROPIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HALLUCINATION; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING; BLOOD; CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; LIVER; MENTAL HEALTH; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL ASPECT; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALZHEIMER DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NOOTROPIC AGENTS; TACRINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031604088     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Albert A, Rubbo SD, Goldaere RJ et al. The influence of chemical constitution on antibacterial activity, Part II: a general survey of acridine series. Br J Exp Pathol 1941; 26: 160-192.
2. Summers VK, Majouski LV, Marsh GM et al. Oral tetrahydroaminoacridine in long term treatment of senile dementia Alzheimer type. N Engl J Med 1986; 315: 1241-1245.
3. Scares JC, Gershon S. THA - historical aspects review of pharmacological properties and therapeutic effects. Dementia 1995; 6: 225-234.
4. Allain H, Belliard S, Michel O et al. La maladie d'Alzheimer; Questions thérapeutiques du moment. La lettre du pharmacologue 1996; 10: 10-13.
5. Circulaire DGS/DHI DSS no 68 du 9/09/1994 relative aux modalitiés de prescription, de dispensation, de prise en charge et de surveillance du bon usage et des effets indésirables du Cognex®.
6. Allain H, Trany A, Belliard S et al. Effect of drug on mnestic performance: a methodological approach. Hum Psychopharmacol 1996; 11: 11-19.
7. McKhannG, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work ground under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
8. Davis KL, Powchik P. Tacrine. Lancet 1995; 345: 625-630.
9. Knapp MJ, Gracon SI, Davis CS et al. Efficacy and safety of high-dose tacrine: a 30-week evaluation. Alzh Dis Assoc Disord 1994; 8: 22-31.
10. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in Alzheimer's disease. Drugs and Aging 1994; 4: 510-540.
11. Park BK, Madden S, Spaldin V et al. Tacrine transaminitis: potential mechanisms. Alzh Dis Assoc Disord 1994; 8: 39-49.
12. Folstein MF, Folstein SE, McHugh P. 'Mini Mental Test': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
13. Knapp MJ, Knopman DS, Soloman PR et al. A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991.
14. Watkins PB, Zinnerman HJ, Knapp MJ et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
15. Hammel P, Larrey D, Bernuau J. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroentol 1990; 12: 329-331.
16. Farlow M, Gracon S, Hershey LA et al. A 12-week, double-blind, placebo-controlled, parallel-group study of tacrine in patients with probable Alzheimer's disease. JAMA 1992; 268: 2523-2529.
17. Blacker D, Albert MS, Bassett SS et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. Arch Neurol 1994; 51: 1198-1204.
18. Lucotte G, Oddoze CH, Michel B. Apolipoprotein E genotype allele Σ4 and response to tacrine in Alzheimer's disease. Alzh Res 1996; 2: 101-102.
19. Eagger SA, Harvey RJ. Clinical heterogeneity: responders to cholinergic therapy. Alzh Dis Assoc Disord 1995; 9: 37-42.
20. Izaks GJ, Gusseklov J, Demout KM et al. Three-year follow-up of Mini-Mental State Examination score in community, resident aged 85 and over. Psychol Med 1995; 25: 841-848.
21. Eagger SA, Richards M, Levy R. Long-term effects of tacrine in Alzheimer's disease: an open study. Int J of Geriatr Psych 1994; 9: 643-647.
22. Allain H, Maruelle L, Beneton C et al. Tacrine et poussées d'hypertension artérielle. Presse Méd 1996; 25: 1388-1389.
23. Allain H, Bentue-Ferrer D, Belliard S. Traitements pharmacologiques de la maladie d'Alzheimer. In: Herrison CH, Touchon J, Enjalbert M, eds. Maladie d'Alzheimer et médecine de rééducation. Paris: Masson, 1996: 127-141.
24. Colaco ALS, Harrington CR. Inhibitors of the maillard reaction. Potential in the treatment of Alzheimer's disease. CNS Drugs 1996; 6: 167-177.
25. Bentue-Ferrer D, Menard G, Allain H. Monoamineoxydase B inhibitors. CNS Drugs 1996; 6: 217-236.
26. Allain H, Derouesne CH, Belliard S et al. Pharmacology of Alzheimer's disease. Prog Med Chem 1997 (in press).
27. Allain H, Lieury A, Lebreton S et al. Les médicaments de la mémoire humaine. J Psychol Psych Gériatr 1996 (in press).
28. Knopman D, Schneider L, Davis K et al. Long term tacrine (Cognex®) treatment effects on nursing home placement and mortality. Neurology 1996; 47: 166-177.